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ST7 is a candidate tumour suppressor gene at human chromosome locus 7q31.1. We have performed mutational analysis of
ST7 in a wide-range of cell lines and primary epithelial cancers and detected only one missense change in a breast cancer cell
line. Other mutations previously found in cell lines and primary tumours were not evident in our analysis. These results imply
that another tumour suppressor gene at this locus may be more important than ST7 in carcinogenesis.
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Many strands of evidence point to an important tumour
suppressor gene (TSG) on human chromosome 7q31. Frequent
deletions within 7q in cytogenetic analyses and a high rate of
loss of heterozygosity (LOH) for 7q microsatellite DNA markers
are both mechanisms commonly encountered in a wide variety
of human tumour types (Zenklusen and Conti, 1996). In addi-
tion, functional complementation assays show that microcell
fusion of an intact chromosome 7 into cancer cell lines with
LOH at 7q31 inhibits tumorigenicity (Ogata et al, 1993; Zenklu-
sen et al, 1994).
A number of candidate genes for the 7q31 TSG have been
described including ST7 (suppression of tumorigenicity 7) formerly
known as RAY1 and HELG (Vincent et al, 2000). Strong evidence
to support ST7 as the key TSG at this locus has recently been
reported by Zenklusen et al (2001). Using a prostate cancer-derived
cell line they have shown that ST7 can suppress in vivo tumorigeni-
city. In addition they described protein-truncating mutations of
ST7 in three out of eight cancer-derived cell lines (three out of
seven breast cancer and none out of one prostate cancer) and in
four out of 10 primary colon carcinomas. The mutations were seen
in exon 3 (four cases), exon 5 (two cases) and exon 12 (once) from
the 16 exons of ST7.
To explore this further, we have performed mutational analysis
of ST7 exons 3, 5 and 12 in a variety of cell lines (cancerous and
non-cancerous) and primary epithelial cancer tissues. Mutation
analysis was carried out using denaturing high performance liquid
chromatography (DHPLC), which is highly speciﬁc and sensitive
for the detection of genetic mutations, including small deletions,
insertions and point mutations (Xiao and Oefner, 2001).
MATERIALS AND METHODS
Intron-speciﬁc primers derived from ST7 cDNA (GenBank
AY009152) aligned to genomic sequence were designed to encom-
pass exons 3, 5 and 12 of ST7 (Table 1). These primers were then
used to amplify the DNA from 34 primary breast cancers, 27
sporadic cutaneous squamous cell carcinomas (SCCs), 34 cancer-
derived cell lines and 27 non-cancerous cell lines (Table 2), by
PCR.
Fifty nanograms of DNA were ampliﬁed in a 50 ml reaction
mixture that contained 200 mM dNTPs, 16NH4 reaction buffer,
1m M MgCl2, 20 pmol primers and 0.5 units Taq polymerase
(Bioline, London, UK). Cycling conditions for exons 3 and 5 were
as follows: 958C for 5 min followed by 35 cycles of 958C for 30 s,
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Table 1 Primer sequences used in PCR reactions (shown in the 5' to 3' direction)
Primer name Forward sequence Reverse sequence PCR product size (bp)
Exon 3 GGCATGTGTACAGAAGTCG AGGTTGTCAACTCCATGGGA 372
Exon 5 TCAACGCCTCTGCAGCTT CTCCCATTCAGAAGGATGTATG 232
Exon 12 GTGTAGATGCTTCCGGGTTG CTGTGGGGATTCCACAGACT 197
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www.bjcancer.com558C for 30 s and 728C for 30 s, and a 10 min ﬁnal extension at
728C. Cycling conditions for exon 12 were identical except for
an annealing temperature of 608C instead of 558C.
Prior to DHPLC analysis, heteroduplex formation of the PCR
products was carried out by heating for 5 min at 948C followed
by cooling to 408C at a rate of 0.038Cs
71. DHPLC was
performed using the Transgenomic WAVE DNA fragment analysis
system (Transgenomic, Crewe, UK). The original PCR products of
any sample traces for which an aberrant DHPLC elution proﬁle
was observed, and all breast and colon cancer samples, were then
sequenced directly. In addition, 10% of the samples with normal
DHPLC elution proﬁles were sequenced. The PCR product was
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Figure 1 Sequence trace for MDA-MB435 breast cancer cell line (lower
trace) showing a G?A substitution at codon 134 of ST7 compared to
wild-type (upper trace).
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Figure 2 DHPLC and sequencing results of the ST7 intronic polymorphism. (A) DHPLC results showing variant traces for CHANG and KB-V1 compared
to the wild-type (WT) trace. (B) Sequencing showing ST7 intron 3 polymorphism in CHANG and KB-V1 at nucleotide 83646, with reference to human
BAC clone CTB-114A6.
Table 2 Details of Cell Lines
Tumour-derived Number Non Number
cell of tumour-derived of
line samples cell lines samples
Breast 4 Colorectal line 2
Colon 4 Normal lymphoblast 3
Ovarian 7 Xeroderma Pigmentosa 6
Pancreatic 4 B-lymphoid line 2
Lung 3 GM00637 clone 5
Prostate 2 Ovarian line 1
Epidermoid carcinoma 2 T-lymphoblastoid line 1
Bladder 1 Liver line 1
Endometrial 1 Ataxia Telangiectasia 1
Testicular 1 Chromosomal aberrant line 1
Hepatocellular 1 Immunodeﬁcient ﬁbroblast 1
Osteosarcoma 1 Virus-transformed ﬁbroblast 1
Cervical 1 Transformed line (not speciﬁed) 1
Lymphoma 1 Transformed primary kidney cells 1
Epithelial tumour 1
(unspeciﬁed)
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and sequenced using Big-Dye terminator chemistry with the same
primers as those used in the original PCR. Sequence analysis was
conducted using an ABI 377 automated DNA sequencer and
Sequence Navigator software (ABI, Warrington, UK).
RESULTS AND DISCUSSION
A single missense mutation in the breast cancer cell line MDA-
MD435 was detected in exon 5 of ST7 (Figure 1). This GCA?ACA
substitution at codon 134 results in an Ala?Thr amino-acid
change. The functional consequence on the ST7 protein of this
alteration is not known (Thomas et al, 2001). We also obtained
variant DHPLC elution proﬁles for the epidermoid oral carcinoma
line KB-V1 and liver cell line CHANG, in the exon 3 PCR
products. The proﬁles from these two samples were similar to each
other (Figure 2A) and subsequent sequencing revealed an identical
T ? G polymorphism in intron 3 (human BAC clone CTB-114A6;
nucleotide 83646) in both cases (Figure 2B). We were unable to
detect the single nucleotide insertions that Zenklusen et al (2001)
reported in the breast cancer cell lines MDA-MB231 and MDA-
MB435 by either DHPLC (Figure 3A) or direct sequencing (Figure
3B). In addition none of the other truncating mutations previously
described were found in any of the samples.
Mutational analysis in a wide-range of cell lines and primary
epithelial tumours has shown that somatic alteration of ST7 rarely
occurs in the exons examined. These results differ markedly from
those recently reported (Zenklusen et al, 2001). This could be
due to the fact that in the previous study all the tumours had been
pre-screened for LOH at 7q31, thus increasing the likelihood of
detecting a mutation. However, we found a high rate of LOH of
42% at 7q31 in breast tumours from our screening panel (using
microsatellite markers D7S522 and D7S677 – data available on
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
5.0
0.0
I
n
t
e
n
s
i
t
y
 
(
m
V
)
I
n
t
e
n
s
i
t
y
 
(
m
V
)
3.3
2.2
1.1
0.0
WT
MB435
1      2       3       4       5       6      7       8      9 1      2       3       4       5       6      7       8      9
Time (min) Time (min)
Exon3
MDA MB435
Exon12
MDA MB231
A   T    T      C    T    C     T    C    C   T    G     A  G
G     C     A      A      A      T    A      C      G      G      A
MB231
WT
A
B
Figure 3 Wild-type proﬁles of DHPLC and direct sequencing for cell lines MDA-MB435 and MDA-MB231. (A) DHPLC traces of ST7 exon 3 for MDA-
MB435 (left) and ST7 exon 12 for MDA-MB231 (right). Cell line traces are identical to wild-type (WT) in both cases. (B) ST7 sequencing of the cell lines
MDA-MB435 (left) and MDA-MB231 (right) for exons 3 and 12 respectively. Arrows show site of mutations described by Zenklusen et al (2001) (466-
467insT in MDA-MB435 and 1364-1365insT in MDA-MB231), which are not seen in these traces. Nucleotides numbered according to GenBank AY009152
but note 4 bp discrepancy compared to Zenklusen et al (2001).
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this level of LOH. In addition, the cutaneous SCCs examined in
this study displayed a lower but still signiﬁcant rate of LOH at
7q31 of 22%.
Other groups have recently found the same missense alteration
in exon 5 in MDA-MB435 that we found (Hughes et al, 2001;
Thomas et al, 2001). They also failed to detect any further coding
mutations in all exons of ST7 in a wide-range of neoplastic carci-
nomas and cell lines, including ovarian, colon, breast, pancreatic
and prostate. Our results extend the spectrum of histological types
examined for ST7 somatic alterations.
In summary, genetic alteration by nucleotide mutation within
ST7 is very rare in epithelial cancers and tumour cell lines. This
suggests that if ST7 is the key TSG at 7q31, it is more likely to
be inactivated by epigenetic mechanisms or haplo-insufﬁciency
than by direct mutation. Alternatively, one of the other TSG, or
an undiscovered gene, at 7q31 is the target involved in carcinogen-
esis at this locus.
ACKNOWLEDGEMENTS
The authors would like to thank Research Cell Services and the
Oligonucleotide Synthesis Group of Cancer Research UK for their
valuable contribution to this study. VL Brown is a Medical
Research Council Clinical Training Fellow.
REFERENCES
Hughes KA, Hurlstone AF, Tobias ES, McFarlane R, Black DM (2001)
Absence of ST7 mutations in tumor-derived cell lines and tumors. Nat
Genet 29: 380–381
Ogata T, Ayusawa D, Namba M, Takahashi E, Oshimura M, Oishi M (1993)
Chromosome 7 suppresses indeﬁnite division of nontumorigenic immor-
talized human ﬁbroblast cell lines KMST-6 and SUSM-1. Mol Cell Biol 13:
6036–6043
Thomas NA, Choong DY, Jokubaitis VJ, Neville PJ, Campbell IG (2001)
Mutation of the ST7 tumor suppressor gene on 7q31.1 is rare in breast,
ovarian and colorectal cancers. Nat Genet 29: 379–380
Vincent JB, Herbrick JA, Gurling HM, Bolton PF, Roberts W, Scherer SW
(2000) Identiﬁcation of a novel gene on chromosome 7q31 that is inter-
rupted by a translocation breakpoint in an autistic individual. Am J
Hum Genet 67: 510–514
Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatogra-
phy: A review. Hum Mutat 17: 439–474
Zenklusen JC, Conti CJ (1996) Cytogenetic, molecular and functional
evidence for novel tumor suppressor genes on the long arm of human
chromosome 7. Mol Carcinog 15: 167–175
Zenklusen JC, Conti CJ, Green ED (2001) Mutational and functional analyses
reveal that ST7 is a highly conserved tumor-suppressor gene on human
chromosome 7q31. Nat Genet 27: 392–398
Zenklusen JC, Oshimura M, Barrett JC, Conti CJ (1994) Inhibition of tumor-
igenicity of a murine squamous cell carcinoma (SCC) cell line by a putative
tumor suppressor gene on human chromosome 7. Oncogene 9: 2817–2825
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
ST7 mutations in cell lines and primary tumours
VL Brown et al
211
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(2), 208–211